Incyte Presents at EHA 2025

Pharmaceutical company Incyte has announced multiple presentations at the European Hematology Association (EHA) 2025 conference. The presentations include new late-breaking data for its mutCALR-Directed Monoclonal Antibody.

Conference Presentations

  • Incyte has announced multiple presentations at the EHA 2025 conference
  • New late-breaking data for mutCALR-Directed Monoclonal Antibody will be presented

Stock Price

Incyte’s stock price has fluctuated within a 52-week range of:

  • Low: 53.56 USD
  • High: 83.95 USD
  • Current price: 68.85 USD

Technical Analysis

  • Price-to-earnings ratio: 242.91
  • Price-to-book ratio: 3.55